- Home
- CELC vs FINV Comparison
CELC vs FINV Comparison
Compare CELC & FINV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- FINV
- Stock Information
- Founded
- CELC 2011
- FINV 2007
- Country
- CELC United States
- FINV China
- Employees
- CELC N/A
- FINV N/A
- Industry
- CELC Medical Specialities
- FINV Finance: Consumer Services
- Sector
- CELC Health Care
- FINV Finance
- Exchange
- CELC Nasdaq
- FINV Nasdaq
- Market Cap
- CELC 2.3B
- FINV 1.9B
- IPO Year
- CELC 2017
- FINV N/A
- Fundamental
- Price
- CELC $50.51
- FINV $7.22
- Analyst Decision
- CELC Strong Buy
- FINV Strong Buy
- Analyst Count
- CELC 6
- FINV 2
- Target Price
- CELC $63.00
- FINV $11.55
- AVG Volume (30 Days)
- CELC 1.0M
- FINV 1.4M
- Earning Date
- CELC 11-13-2025
- FINV 11-17-2025
- Dividend Yield
- CELC N/A
- FINV 3.93%
- EPS Growth
- CELC N/A
- FINV 32.63
- EPS
- CELC N/A
- FINV 1.49
- Revenue
- CELC N/A
- FINV $1,927,901,951.00
- Revenue This Year
- CELC N/A
- FINV $11.56
- Revenue Next Year
- CELC N/A
- FINV $8.06
- P/E Ratio
- CELC N/A
- FINV $4.85
- Revenue Growth
- CELC N/A
- FINV 7.84
- 52 Week Low
- CELC $7.58
- FINV $5.72
- 52 Week High
- CELC $63.06
- FINV $11.08
- Technical
- Relative Strength Index (RSI)
- CELC 49.45
- FINV 34.47
- Support Level
- CELC $44.42
- FINV $7.30
- Resistance Level
- CELC $52.76
- FINV $7.71
- Average True Range (ATR)
- CELC 3.10
- FINV 0.24
- MACD
- CELC -1.11
- FINV 0.01
- Stochastic Oscillator
- CELC 51.39
- FINV 13.02
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About FINV FinVolution Group
FinVolution Group is a provider of online consumer finance in China. The company offers various loan products, making financial services available to borrowers anytime, anywhere; designs a loan transaction process, and offers tailored risk-based pricing. It offers short-term loans to borrowers to meet immediate credit needs while allowing them to gradually establish their credit history through activities on the company's platform. The company generates revenues from fees charged to borrowers. The Group's long-lived assets are located in the PRC, and its revenues are derived from within the PRC.